Literature DB >> 19306859

Proteomics-based identification of alpha1-antitrypsin and haptoglobin precursors as novel serum markers in infiltrating ductal breast carcinomas.

Bechr Hamrita1, Karim Chahed, Mounir Trimeche, Christelle Lemaitre Guillier, Philippe Hammann, Anouar Chaïeb, Sadok Korbi, Lotfi Chouchane.   

Abstract

BACKGROUND: The identification of pathological markers of breast cancer for either diagnosis, treatment response or for survival is of critical importance.
METHODS: Serum protein profiling using 2-DE separations coupled to matrix-assisted laser desorption ionization mass spectrometry has been used to explore protein alterations in patients with infiltrating ductal breast carcinomas (IDCA). Sera from 39 breast cancer patients and 40 healthy controls were selected for screening study using 2-DE combined with MS. The protein expression patterns obtained after the depletion of high abundance proteins was determined by coomassie blue G-250 stain after 2-DE electrophoresis.
RESULTS: Six proteins that expressed differentially in the IDCA group were found. The expression levels of four isoforms corresponding to haptoglobin precursor and two isoforms of alpha1-antitrypsin precursor (alpha1-AT) were upregulated in sera from breast cancer patients. There was an increased expression of both proteins in the sera of patients with various tumor stages (I, II, III) in comparison to healthy women. Applying immunohistochemistry, we further validated alpha1-AT immunoreactivity in 51 formalin-fixed paraffin-embedded sections of breast tumors. Enhanced expression of alpha1-AT like activity has been found in IDCA breast tumors, as well as, in different histological types of breast cancer. No significant association has been found with lymph node occurrence, while in high tumor categories a tendency to an increased expression of alpha1-AT has been found, thereby suggesting a possible role of this protein in tumor growth.
CONCLUSIONS: These proteins may constitute new and useful markers of breast cancer that offer a clue to a better understanding of inflammatory pathways and carcinogenesis events linked to breast cancer progression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19306859     DOI: 10.1016/j.cca.2009.03.033

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  10 in total

1.  Urinary glycoprotein biomarker discovery for bladder cancer detection using LC/MS-MS and label-free quantification.

Authors:  Na Yang; Shun Feng; Kerby Shedden; Xiaolei Xie; Yashu Liu; Charles J Rosser; David M Lubman; Steven Goodison
Journal:  Clin Cancer Res       Date:  2011-04-01       Impact factor: 12.531

2.  Diagnostic potential of urinary α1-antitrypsin and apolipoprotein E in the detection of bladder cancer.

Authors:  Virginia Urquidi; Steve Goodison; Shanti Ross; Myron Chang; Yunfeng Dai; Charles J Rosser
Journal:  J Urol       Date:  2012-10-22       Impact factor: 7.450

3.  Lung cancer proteomics: recent advances in biomarker discovery.

Authors:  Paola Indovina; Eleonora Marcelli; Pasquale Maranta; Giulio Tarro
Journal:  Int J Proteomics       Date:  2011-09-15

4.  Correspondence between salivary proteomic pattern and clinical course in primary Sjögren syndrome and non-Hodgkin's lymphoma: a case report.

Authors:  Chiara Baldini; Laura Giusti; Federica Ciregia; Ylenia Da Valle; Camillo Giacomelli; Elena Donadio; Francesco Ferro; Sara Galimberti; Valentina Donati; Laura Bazzichi; Stefano Bombardieri; Antonio Lucacchini
Journal:  J Transl Med       Date:  2011-11-02       Impact factor: 5.531

5.  Identification of Potential Glycoprotein Biomarkers in Estrogen Receptor Positive (ER+) and Negative (ER-) Human Breast Cancer Tissues by LC-LTQ/FT-ICR Mass Spectrometry.

Authors:  Suzan M Semaan; Xu Wang; Alan G Marshall; Qing-Xiang Amy Sang
Journal:  J Cancer       Date:  2012-06-21       Impact factor: 4.207

6.  Investigation of CCL18 and A1AT as potential urinary biomarkers for bladder cancer detection.

Authors:  Makito Miyake; Shanti Ross; Adrienne Lawton; Myron Chang; Yunfeng Dai; Lourdes Mengual; Antonio Alcaraz; Evan Gomes Giacoia; Steve Goodison; Charles J Rosser
Journal:  BMC Urol       Date:  2013-09-05       Impact factor: 2.264

Review 7.  Inflammatory Markers and MicroRNAs: The Backstage Actors Influencing Prognosis in Colorectal Cancer Patients.

Authors:  Rihab Nasr; Miza Salim Hammoud; Farah Nassar; Deborah Mukherji; Ali Shamseddine; Sally Temraz
Journal:  Int J Mol Sci       Date:  2018-06-26       Impact factor: 5.923

8.  Proteomic Profiling for Serum Biomarkers in Mice Exposed to Ionizing Radiation.

Authors:  Jinfeng Huang; Qi Wang; Yingchun Hu; Zhenhua Qi; Zhongwu Lin; Wantao Ying; Meijuan Zhou
Journal:  Dose Response       Date:  2019-12-12       Impact factor: 2.658

9.  A bead-based multiplexed immunoassay to evaluate breast cancer biomarkers for early detection in pre-diagnostic serum.

Authors:  Annemieke W J Opstal-van Winden; Wendy Rodenburg; Jeroen L A Pennings; Conny T M van Oostrom; Jos H Beijnen; Petra H M Peeters; Carla H van Gils; Annemieke de Vries
Journal:  Int J Mol Sci       Date:  2012-10-22       Impact factor: 5.923

10.  Proteome Profiling of Urinary Exosomes Identifies Alpha 1-Antitrypsin and H2B1K as Diagnostic and Prognostic Biomarkers for Urothelial Carcinoma.

Authors:  Shih-Yi Lin; Chao-Hsiang Chang; His-Chin Wu; Ching-Chan Lin; Kai-Po Chang; Chi-Rei Yang; Chi-Ping Huang; Wu-Huei Hsu; Chiz-Tzung Chang; Chao-Jung Chen
Journal:  Sci Rep       Date:  2016-09-30       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.